Download MendeleyStructure of the AML1-ETO eTAFH domain-HEB peptide complex and its contribution to AML1-ETO activity.
Park, S., Chen, W., Cierpicki, T., Tonelli, M., Cai, X., Speck, N.A., Bushweller, J.H.(2009) Blood 113: 3558-3567
- PubMed: 19204326
- DOI: https://doi.org/10.1182/blood-2008-06-161307
- Primary Citation of Related Structures:
2KNH - PubMed Abstract:
AML1-ETO is the chimeric protein product of the t(8;21) in acute myeloid leukemia. The ETO portion of the fusion protein includes the eTAFH domain, which is homologous to several TATA binding protein-associated factors (TAFs) and interacts with E proteins (E2A and HEB). It has been proposed that AML1-ETO-mediated silencing of E protein function might be important for t(8;21) leukemogenesis. Here, we determined the solution structure of a complex between the AML1-ETO eTAFH domain and an interacting peptide from HEB. On the basis of the structure, key residues in AML1-ETO for HEB association were mutated. These mutations do not impair the ability of AML1-ETO to enhance the clonogenic capacity of primary mouse bone marrow cells and do not eliminate its ability to repress proliferation or granulocyte differentiation. Therefore, the eTAFH-E protein interaction appears to contribute relatively little to the activity of AML1-ETO.
Organizational Affiliation:
Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, VA 22908, USA.
